Therefore, our model of tumor clearance depends upon the heteroclitic anti-CSDE1P5S/anti-CSDE1WT T-cell response being potent enough to clear that proportion of tumor cells in which the CSDE1P5S mutation had not evolved following VSV-IFNβ therapy. This evidence concerns the gene IFNB1 and neoplasm.